ATE175350T1 - Zusammensetzung zur vorbeugung und behandlung von myopie - Google Patents

Zusammensetzung zur vorbeugung und behandlung von myopie

Info

Publication number
ATE175350T1
ATE175350T1 AT94115648T AT94115648T ATE175350T1 AT E175350 T1 ATE175350 T1 AT E175350T1 AT 94115648 T AT94115648 T AT 94115648T AT 94115648 T AT94115648 T AT 94115648T AT E175350 T1 ATE175350 T1 AT E175350T1
Authority
AT
Austria
Prior art keywords
myopia
treatment
prophylaxis
composition
preventing
Prior art date
Application number
AT94115648T
Other languages
English (en)
Inventor
Toshiro Shigemitsu
Noriko Watanabe
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE175350T1 publication Critical patent/ATE175350T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT94115648T 1993-10-07 1994-10-05 Zusammensetzung zur vorbeugung und behandlung von myopie ATE175350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25138393 1993-10-07
JP1253794 1994-02-04

Publications (1)

Publication Number Publication Date
ATE175350T1 true ATE175350T1 (de) 1999-01-15

Family

ID=26348167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94115648T ATE175350T1 (de) 1993-10-07 1994-10-05 Zusammensetzung zur vorbeugung und behandlung von myopie

Country Status (18)

Country Link
US (1) US5519030A (de)
EP (1) EP0647445B1 (de)
KR (1) KR100193406B1 (de)
CN (1) CN1108095A (de)
AT (1) ATE175350T1 (de)
AU (1) AU677860B2 (de)
BR (1) BR9404007A (de)
CA (1) CA2133805A1 (de)
CZ (1) CZ244994A3 (de)
DE (1) DE69415757T2 (de)
ES (1) ES2126039T3 (de)
FI (1) FI944687A7 (de)
HU (1) HUT71112A (de)
NO (1) NO943749L (de)
NZ (1) NZ264616A (de)
PL (1) PL305352A1 (de)
SK (1) SK121394A3 (de)
TW (1) TW282471B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR980008226A (ko) * 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
SE0002211D0 (sv) * 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
MD38Z5 (ro) * 2009-02-20 2010-02-28 Татьяна ГИДИРИМСКИЙ Metodă de corecţie a vederii la slab văzători
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JPH06110587A (ja) * 1992-09-28 1994-04-22 Omron Corp 自動取引き機の電源制御方法とその装置

Also Published As

Publication number Publication date
KR100193406B1 (ko) 1999-06-15
FI944687L (fi) 1995-04-08
US5519030A (en) 1996-05-21
CA2133805A1 (en) 1995-04-08
HU9402883D0 (en) 1995-01-30
SK121394A3 (en) 1995-07-11
ES2126039T3 (es) 1999-03-16
BR9404007A (pt) 1995-06-13
EP0647445A1 (de) 1995-04-12
NO943749D0 (no) 1994-10-06
PL305352A1 (en) 1995-04-18
CN1108095A (zh) 1995-09-13
KR950010896A (ko) 1995-05-15
FI944687A0 (fi) 1994-10-06
EP0647445B1 (de) 1999-01-07
TW282471B (de) 1996-08-01
AU677860B2 (en) 1997-05-08
CZ244994A3 (en) 1995-04-12
DE69415757D1 (de) 1999-02-18
AU7441794A (en) 1995-04-27
FI944687A7 (fi) 1995-04-08
NZ264616A (en) 1997-06-24
NO943749L (no) 1995-04-10
DE69415757T2 (de) 1999-06-10
HUT71112A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
GR3005586T3 (de)
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE184483T1 (de) Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
EP0285278A3 (en) Method of treating anxiety with tetrahydrobenzûc,d¨indole-6-carboxamides
ATE175350T1 (de) Zusammensetzung zur vorbeugung und behandlung von myopie
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE60123528D1 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
DE69421457D1 (de) Verwendung von N-(Pyridinyl)-1H-Indol-1-Aminen zur Herstellung eines Medikamentes zur Behandlung von zwangsneurotischen Erkrankungen
DE69411852D1 (de) Indolderivate, ihre Salze und sie enthaltende Arzneimittel zur Behandlung von Herzkrankheiten
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
RU94035672A (ru) Композиция для профилактики и лечения близорукости, способ ее получения
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
TH17660A (th) สารผสมสำหรับป้องกันและรักษาสายตาสั้น
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ZA885358B (en) Uricosuric composition
DE59409129D1 (de) Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties